Health & Biotech
US FDA extends orphan drug designation for Race Oncology’s lead asset
Health & Biotech
ASX Health Stocks: Orthocell seeks TGA approval; Race Oncology gets FDA nod
Health & Biotech
Althea aims for positive earnings after restructure, leap into US cannabis beverage market
Health & Biotech
Neurotech’s cannabinoid drug blazes new path for treating rare neurological disorder in kids
Health & Biotech
PharmAust’s monepantel drug could be a game-changer for MND/ALS patients, new data shows
Health & Biotech
The Calmer Co jumps 100pc on strong momentum in May, driven by eCommerce sales
Health & Biotech
ASX Health Stocks: Genetic Signatures gets FDA approval; Optiscan unveils new device
Health & Biotech
‘Significant milestone’: Optiscan soars on new InVue imaging device for precision surgery
Health & Biotech
ASX Health Winners in May: LTR Pharma leads, and why hopes are high for biotech stocks this year
Health & Biotech
AdAlta secures $1.9m from exercise of options to advance critical discovery programs
Health & Biotech
ASX Health Stocks: INOVIQ pops 45pc after revealing breakthrough exosome therapy to kill breast cancer
Health & Biotech
ScoPo’s (actually Wilkie’s) Powerplays: ASX health stocks fall but Dimerix and Avita soar
Featured Health & Biotech Stocks
Health & Biotech
Healthcare stocks are as varied as the solutions they are working to solve. The sector covers biotech stocks developing breakthrough pharmaceutical drugs and vaccines to medtech companies launching the latest and greatest medical devices they hope will change the face of healthcare.
Even the ‘budding’ medical cannabis industry is in the mix as researchers explore new applications and treatments.
If you want to know what’s happening with emerging health stocks on the ASX, Stockhead has you covered, with daily stock news, expert insight and research. You can also recap broader industry trends and recent share price movements across the sector in our regular ‘Check Up’ feature.
Accurate, up-to-date news stories are important, especially in the health sector where progress is often slow and risk often high. That’s why we’re focused on helping small cap investors make sense of the medical jargon.